Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1080/14760584.2021.1903879 http://scihub22266oqcxt.onion/10.1080/14760584.2021.1903879 33851875!8054487!33851875     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33851875&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Expert+Rev+Vaccines 2021 ; 20 (4): 365-373 Nephropedia Template TP {{tp|p=33851875|t=2021. Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies |pdf=|usr=}}{{33851875}} gab.com Text Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies JO: Expert Rev Vaccines http://www.kidney.de/pget.php?&tw=1&pmid=33851875 #FOAvip INTRODUCTION: As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread, several variants have emerged. Variants B.1.1.7 and B.1.351 have attracted significant attention owing to their widespread transmission and possible immune evasion. A total of 19 SARS-CoV-2 vaccines based on original strains have entered clinical studies, including nine vaccines that have obtained emergency use or conditional marketing authorizations. However, newly emerging variants may affect their protective efficacy. Decreased efficacy of the Novartis, Johnson & Johnson, and AstraZeneca vaccines against B.1.351 has been reported. The spread of variants creates a tremendous challenge for the prevention and control of the SARS-CoV-2 pandemic via vaccination. Several response strategies, including accelerating massive rollouts of current vaccines, increasing vaccine immunogenicity by increasing vaccination doses, and accelerating next-generation vaccines against variants, have been suggested. AREAS COVERED: SARS-CoV-2 vaccine efficacy against variants and response strategies for emerging variants. EXPERT OPINION: Current SARS-CoV-2 vaccines authorized for emergency use or under clinical trials have shown certain advantages in providing adequate protection against new variants. We analyzed the effects of reported variants on neutralizing antibodies and the protective efficacy of different vaccines and propose strategies for applying current vaccines against variants and developing next-generation vaccines. Twit Text FOAVip Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies ????Expert Rev Vaccines http://www.kidney.de/pget.php?&tw=1&pmid=33851875 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33851875 #FOAvip English Wikipedia <ref>{{Cite pmid|33851875}}</ref> Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies #MMPMID33851875 Bian L; Gao F; Zhang J; He Q; Mao Q; Xu M; Liang Z Expert Rev Vaccines 2021[Apr]; 20 (4): 365-373 PMID33851875show ga INTRODUCTION: As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic continues to spread, several variants have emerged. Variants B.1.1.7 and B.1.351 have attracted significant attention owing to their widespread transmission and possible immune evasion. A total of 19 SARS-CoV-2 vaccines based on original strains have entered clinical studies, including nine vaccines that have obtained emergency use or conditional marketing authorizations. However, newly emerging variants may affect their protective efficacy. Decreased efficacy of the Novartis, Johnson & Johnson, and AstraZeneca vaccines against B.1.351 has been reported. The spread of variants creates a tremendous challenge for the prevention and control of the SARS-CoV-2 pandemic via vaccination. Several response strategies, including accelerating massive rollouts of current vaccines, increasing vaccine immunogenicity by increasing vaccination doses, and accelerating next-generation vaccines against variants, have been suggested. AREAS COVERED: SARS-CoV-2 vaccine efficacy against variants and response strategies for emerging variants. EXPERT OPINION: Current SARS-CoV-2 vaccines authorized for emergency use or under clinical trials have shown certain advantages in providing adequate protection against new variants. We analyzed the effects of reported variants on neutralizing antibodies and the protective efficacy of different vaccines and propose strategies for applying current vaccines against variants and developing next-generation vaccines. |Antibodies, Neutralizing/genetics/immunology[MESH] |COVID-19 Serotherapy[MESH] |COVID-19 Vaccines/*administration & dosage/immunology[MESH] |COVID-19/*genetics/immunology/*prevention & control/therapy[MESH] |Humans[MESH] |Immunization, Passive[MESH] |SARS-CoV-2/*genetics/immunology[MESH]Effects of SARS-CoV-2 variants on vaccine efficacy and response strate(epmc).pdf DeepDyve Pubget Overpricing